RELATED STUDY
Case Report: Lennox-Gastaut Epileptic Encephalopathy Responsive to Cannabidiol Treatment Associated With a Novel de novo Mosaic SHANK1 Variant
Key Findings: This case report presents a pediatric patient with SHANK1 Gly126Arg variant and treatment-resistant epilepsy. He was treated with cannabidiol on a clinical trial and remained without seizures for more than 4 years after.
Type of Study: Meta-analysis
Study Sample Size: 1
Study Result: Positive
Research Location(s): Poland
Year of Pub: 2021
Cannabinoids Studied: Cannabidiol (CBD)
Phytocannabinoid Source: Unspecified
Chemotype: Chemotype III
Ligands Studied: Glutamate
DOSING DETAILS 
Study Dosing Objective: Effective Dose
Established Protocol: Effective dose
Route of Administration: Oral (Ingestion)
Cannabinoid Ratio: (CBD) 0 
Dosing Regimen: CBD (30 mg/kg/day)
Clinical Relevance: After cannabidiol administration, the epileptic seizures stopped, and the patient has been seizure-free for >4 years now.
Citation: Paprocka J, et al. Case Report: Lennox-Gastaut Epileptic Encephalopathy Responsive to Cannabidiol Treatment Associated With a Novel de novo Mosaic SHANK1 Variant. Front Genet. 2021; 12:735292. doi: 10.3389/fgene.2021.735292
Authors: Paprocka J, Ziętkiewicz S, Kosińska J, Kaczorowska E, Płoski R
